Last reviewed · How we verify
DETRUSITOL
DETRUSITOL, marketed by Rambam Health Care Campus, is an established treatment in its therapeutic class. The key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | DETRUSITOL |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (PHASE2)
- A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder (PHASE3)
- A Study of YM178 in Subjects With Symptoms of Overactive Bladder (PHASE3)
- Pharmacological vs Surgical Treatment for Mixed Incontinence (PHASE4)
- Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
- Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB (PHASE4)
- Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients (PHASE4)
- Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DETRUSITOL CI brief — competitive landscape report
- DETRUSITOL updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI